Brokers Suggest Investing in Celestica (CLS): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?Let's take a look at what these Wall Street heavyweights have to say about Celestica (CLS) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Celestica currently has an average brokerage recommendation (ABR) of 1.40, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 10 brokerage firms. An ABR of 1.40 approximates between Strong Buy and Buy.Of the 10 recommendations that derive the current ABR, seven are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 70% and 20% of all recommendations.Brokerage Recommendation Trends for CLSCheck price target & stock forecast for Celestica here>>>The ABR suggests buying Celestica, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement.With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near -term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.ABR Should Not Be Confused With Zacks RankAlthough both Zacks Rank and ABR are displayed in a range of 1-5, they are different measures altogether.The ABR is calculated solely based on brokerage recommendations and is typically displayed with decimals (example: 1.28). In contrast, the Zacks Rank is a quantitative model allowing investors to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is CLS Worth Investing In?In terms of earnings estimate revisions for Celestica, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at $5.05.Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Celestica. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for Celestica.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Celestica, Inc. (CLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Quelle: Zacks
Nachrichten zu Celestica Inc. (Sub Voting)
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Analysen zu Celestica Inc. (Sub Voting)
Datum | Rating | Analyst | |
---|---|---|---|
17.08.2017 | Celestica Buy | Standpoint Research | |
27.01.2017 | Celestica Hold | Stifel, Nicolaus & Co., Inc. | |
18.11.2016 | Celestica Hold | Standpoint Research | |
15.01.2016 | Celestica Sector Perform | RBC Capital Markets | |
30.10.2015 | Celestica Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
17.08.2017 | Celestica Buy | Standpoint Research | |
27.01.2017 | Celestica Hold | Stifel, Nicolaus & Co., Inc. | |
30.10.2014 | Celestica Buy | Standpoint Research | |
25.10.2012 | Celestica buy | Paradigm Capital | |
17.10.2012 | Celestica sector outperform | Scotia Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
18.11.2016 | Celestica Hold | Standpoint Research | |
15.01.2016 | Celestica Sector Perform | RBC Capital Markets | |
30.10.2015 | Celestica Sector Perform | RBC Capital Markets | |
21.10.2015 | Celestica Sector Perform | RBC Capital Markets | |
07.12.2012 | Celestica sector perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
20.06.2011 | Celestica sell | Citigroup Corp. | |
22.02.2007 | Celestica reduce | UBS | |
22.07.2005 | Update Celestica Inc. (Sub Voting): Underperform | Bear Stearns |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Celestica Inc. (Sub Voting) nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen